Global Action to Drive Innovation in Alzheimer's Disease and Other Dementias: Connecting Research, Regulation and Access

Oecd

No 31, OECD Science, Technology and Industry Policy Papers from OECD Publishing

Abstract: Policymakers and the research community have an integral leadership role to foster collaborative efforts to deliver the best available science for evidence based policies and approval processes. The second Lausanne Workshop of December 2015 reviewed the policy and stakeholder actions needed to accelerate biomedical research and health innovation for Alzheimer’s disease and other dementias. The agenda featured developments in regulatory and access pathways for potential innovations in dementia. Participants discussed the perspectives of regulators and payers, specifically the evidence and tools needed to support regulatory and payer evaluation of innovations. A particular focus was placed on the large and growing societal implications of Alzheimer’s disease and the heightened urgency to define sustainable access strategies for future diagnostics and therapies. There is consensus across all stakeholders to move from global agenda setting in Alzheimer’s disease to action oriented programmes and implementation.

Date: 2016-09-09
New Economics Papers: this item is included in nep-hea and nep-ino
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1787/5jlr8vfzdsr2-en (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oec:stiaac:31-en

Access Statistics for this paper

More papers in OECD Science, Technology and Industry Policy Papers from OECD Publishing Contact information at EDIRC.
Bibliographic data for series maintained by ().